Search

Your search keyword '"Yang, Joanna C"' showing total 49 results
Start Over Author "Yang, Joanna C"
49 results on '"Yang, Joanna C"'

5. Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Clinical Trial

Author

Gillespie, Erin F., primary, Yang, Joanna C., additional, Mathis, Noah J., additional, Marine, Catherine B., additional, White, Charlie, additional, Zhang, Zhigang, additional, Barker, Christopher A., additional, Kotecha, Rupesh, additional, McIntosh, Alyson, additional, Vaynrub, Max, additional, Bartelstein, Meredith K., additional, Mitchell, Aaron, additional, Guttmann, David M., additional, Yerramilli, Divya, additional, Higginson, Daniel S., additional, Yamada, Yoshida J., additional, Kohutek, Zachary A., additional, Powell, Simon N., additional, Tsai, Jillian, additional, and Yang, Jonathan T., additional

Published
2024
Full Text
View/download PDF

13. Multi-Institutional Review of Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas

Author

Yegya-Raman, Nikhil, primary, Wright, Christopher M., additional, Figura, Nicholas B., additional, Zhang, Siqi, additional, Chew, Jessica J., additional, Burke, Skyler E., additional, Sim, Austin J., additional, LaRiviere, Michael J., additional, Baron, Jonathan A., additional, Sinha, Sumi, additional, Yang, Joanna C., additional, Robinson, Timothy J., additional, Jain, Michael D., additional, Maity, Amit, additional, Paydar, Ima, additional, Tseng, Yolanda D., additional, Braunstein, Steve E., additional, Schuster, Stephen J., additional, Chong, Elise A., additional, and Plastaras, John P., additional

Published
2022
Full Text
View/download PDF

14. Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

Author

Stuver, Robert, primary, Michaud, Laure, additional, Casulo, Carla, additional, Advani, Ranjana H., additional, Budde, Elizabeth L., additional, Barr, Paul M., additional, Batlevi, Connie Lee, additional, Caron, Philip C, additional, Constine, Louis S., additional, Dandapani, Savita, additional, Drullinsky, Pamela, additional, Friedberg, Jonathan W., additional, Grieve, Clare, additional, Hamilton, Audrey, additional, Hamlin, Paul A., additional, Hoppe, Richard, additional, Horwitz, Steven M., additional, Khan, Niloufer, additional, Matasar, Matthew J., additional, Noy, Ariela, additional, Palomba, M.Lia, additional, Schoder, Heiko, additional, Straus, David J., additional, Vemuri, Shreya, additional, Yahalom, Joachim, additional, Yang, Joanna C., additional, Younes, Anas, additional, Zelenetz, Andrew D., additional, Moskowitz, Craig H., additional, Kumar, Anita, additional, and Moskowitz, Alison J., additional

Published
2022
Full Text
View/download PDF

15. PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma

Author

Lo, Andrea C, James, Lyndon P, Prica, Anca, Raymakers, Adam, Peacock, Stuart, Qu, Melody, Louie, Alex V, Savage, Kerry J, Sehn, Laurie H, Hodgson, David, Yang, Joanna C, Eich, Hans T T, Wirth, Andrew, Hunink, M G Myriam, Lo, Andrea C, James, Lyndon P, Prica, Anca, Raymakers, Adam, Peacock, Stuart, Qu, Melody, Louie, Alex V, Savage, Kerry J, Sehn, Laurie H, Hodgson, David, Yang, Joanna C, Eich, Hans T T, Wirth, Andrew, and Hunink, M G Myriam

Abstract

The objective was to assess the cost-effectiveness of staging PET/CT in early-stage follicular lymphoma (FL) from the Canadian health-care system perspective. Methods: The study population was FL patients staged as early-stage using conventional CT imaging and planned for curative-intent radiation therapy (RT). A decision analytic model simulated the management after adding staging PET/CT versus using staging CT alone. In the no-PET/CT strategy, all patients proceeded to curative-intent RT as planned. In the PET/CT strategy, PET/CT information could result in an increased RT volume, switching to a noncurative approach, or no change in RT treatment as planned. The subsequent disease course was described using a state-transition cohort model over a 30-y time horizon. Diagnostic characteristics, probabilities, utilities, and costs were derived from the literature. Baseline analysis was performed using quality-adjusted life years (QALYs), costs (2019 Canadian dollars), and the incremental cost-effectiveness ratio. Deterministic sensitivity analyses were conducted, evaluating net monetary benefit at a willingness-to-pay threshold of $100,000/QALY. Probabilistic sensitivity analysis using 10,000 simulations was performed. Costs and QALYs were discounted at a rate of 1.5%. Results: In the reference case scenario, staging PET/CT was the dominant strategy, resulting in an average lifetime cost saving of $3,165 and a gain of 0.32 QALYs. In deterministic sensitivity analyses, the PET/CT strategy remained the preferred strategy for all scenarios supported by available data. In probabilistic sensitivity analysis, the PET/CT strategy was strongly dominant in 77% of simulations (i.e., reduced cost and increased QALYs) and was cost-effective in 89% of simulations (i.e., either saved costs or had an incremental cost-effectiveness ratio below $100,000/QALY). Conclusion: Our analysis showed that the use of PET/CT to stage early-stage FL patients reduces cost and improves QALYs. Pat

Published
2022

16. NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022

Author

Hoppe, Richard T., primary, Advani, Ranjana H., additional, Ai, Weiyun Z., additional, Ambinder, Richard F., additional, Armand, Philippe, additional, Bello, Celeste M., additional, Benitez, Cecil M., additional, Chen, Weina, additional, Dabaja, Bouthaina, additional, Daly, Megan E., additional, Gordon, Leo I., additional, Hansen, Neil, additional, Herrera, Alex F., additional, Hochberg, Ephraim P., additional, Johnston, Patrick B., additional, Kaminski, Mark S., additional, Kelsey, Christopher R., additional, Kenkre, Vaishalee P., additional, Khan, Nadia, additional, Lynch, Ryan C., additional, Maddocks, Kami, additional, McConathy, Jonathan, additional, Metzger, Monika, additional, Morgan, David, additional, Mulroney, Carolyn, additional, Pullarkat, Sheeja T., additional, Rabinovitch, Rachel, additional, Rosenspire, Karen C., additional, Seropian, Stuart, additional, Tao, Randa, additional, Torka, Pallawi, additional, Winter, Jane N., additional, Yahalom, Joachim, additional, Yang, Joanna C., additional, Burns, Jennifer L., additional, Campbell, Mallory, additional, and Sundar, Hema, additional

Published
2022
Full Text
View/download PDF

20. PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma

Author

Lo, Andrea C., primary, James, Lyndon P., additional, Prica, Anca, additional, Raymakers, Adam, additional, Peacock, Stuart, additional, Qu, Melody, additional, Louie, Alex V., additional, Savage, Kerry J., additional, Sehn, Laurie H., additional, Hodgson, David, additional, Yang, Joanna C., additional, Eich, Hans T.T., additional, Wirth, Andrew, additional, and Hunink, M.G. Myriam, additional

Published
2021
Full Text
View/download PDF

23. Additional file 5 of Early palliative radiation versus observation for high-risk asymptomatic or minimally symptomatic bone metastases: study protocol for a randomized controlled trial

Author

Rosen, Daniel B., Benjamin, Cory D., Yang, Joanna C., Doyle, Connor, Zhigang Zhang, Barker, Chris A., Vaynrub, Max, T. Jonathan Yang, and Gillespie, Erin F.

Subjects
ComputingMilieux_LEGALASPECTSOFCOMPUTING
Abstract

Additional file 5. EuroQol EQ-5D-5L questionnaire (hyperlink and licensing information).

Published
2020
Full Text
View/download PDF

24. Additional file 4 of Early palliative radiation versus observation for high-risk asymptomatic or minimally symptomatic bone metastases: study protocol for a randomized controlled trial

Author

Rosen, Daniel B., Benjamin, Cory D., Yang, Joanna C., Doyle, Connor, Zhigang Zhang, Barker, Chris A., Vaynrub, Max, T. Jonathan Yang, and Gillespie, Erin F.

Subjects
genetic structures, humanities
Abstract

Additional file 4. Cover letter for patient QoL packet.

Published
2020
Full Text
View/download PDF

26. Additional file 6 of Early palliative radiation versus observation for high-risk asymptomatic or minimally symptomatic bone metastases: study protocol for a randomized controlled trial

Author

Rosen, Daniel B., Benjamin, Cory D., Yang, Joanna C., Doyle, Connor, Zhigang Zhang, Barker, Chris A., Vaynrub, Max, T. Jonathan Yang, and Gillespie, Erin F.

Abstract

Additional file 6. Adverse Event definitions, process of attribution to radiation therapy, and follow-up.

Published
2020
Full Text
View/download PDF

32. A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Author

Kumar, Anita, primary, Casulo, Carla, additional, Advani, Ranjana H, additional, Budde, Lihua E, additional, Barr, Paul M., additional, Batlevi, Connie Lee, additional, Caron, Philip, additional, Constine, Louis S., additional, Dandapani, Savita, additional, Drill, Esther, additional, Drullinsky, Pamela, additional, Friedberg, Jonathan W., additional, Grieve, Clare, additional, Hamilton, Audrey, additional, Hamlin, Paul A., additional, Hoppe, Richard T, additional, Horwitz, Steven M., additional, Matasar, Matthew J, additional, McCall, Susan Jennifer, additional, Moskowitz, Alison J., additional, Noy, Ariela, additional, Palomba, Maria Lia, additional, Schoder, Heiko, additional, Straus, David J., additional, Vemuri, Shreya, additional, Yang, Joanna C, additional, Younes, Anas, additional, Zelenetz, Andrew D., additional, Yahalom, Joachim, additional, and Moskowitz, Craig H., additional

Published
2019
Full Text
View/download PDF

40. A Pilot Study of Brentuximab Vedotin and AVD Chemotherapy Followed By 20 Gy Involved-Site Radiotherapy in Early Stage, Unfavorable Risk Hodgkin Lymphoma

Author

Kumar, Anita, primary, Casulo, Carla, additional, Advani, Ranjana H., additional, Budde, Lihua, additional, Barr, Paul M., additional, Batlevi, Connie L., additional, Caron, Philip, additional, Chen, Robert W., additional, Constine, Louis S., additional, Courtien, Amanda, additional, Dandapani, Savita, additional, Drullinsky, Pamela, additional, Friedberg, Jonathan W., additional, Gerecitano, John, additional, Hamilton, Audrey, additional, Hamlin, Paul A., additional, Hoppe, Richard T., additional, Horwitz, Steven M., additional, Matasar, Matthew J., additional, Miller, Shoshana T., additional, Moskowitz, Alison J., additional, Noy, Ariela, additional, Palomba, Maria L., additional, Portlock, Carol S., additional, Schoder, Heiko, additional, Straus, David J., additional, Yang, Joanna C., additional, Younes, Anas, additional, Zelenetz, Andrew D., additional, Zhang, Zhigang, additional, Yahalom, Joachim, additional, and Moskowitz, Craig H., additional

Published
2017
Full Text
View/download PDF

41. Intensity Modulated Radiation Therapy with Dose-painting: A Brain-sparing Technique for Intracranial Germ Cell Tumors

Author

Yang, Joanna C., Terezakis, Stephanie A., Dunkel, Ira J., Gilheeney, Stephen W., and Wolden, Suzanne L.

Subjects
Male, Young Adult, Adolescent, Brain Neoplasms, Radiotherapy Planning, Computer-Assisted, Humans, Dose-Response Relationship, Radiation, Female, Radiotherapy Dosage, Radiotherapy, Intensity-Modulated, Neoplasms, Germ Cell and Embryonal, Child, Article
Abstract

We sought to assess patterns of failure in pediatric patients with intracranial germ cell tumors (GCT) treated with intensity-modulated radiation therapy with dose painting (DP-IMRT).Between July 2007 and October 2013, 11 patients with localized GCT-five germinomas and six nongerminoma GCT (NGGCT)-received definitive treatment with DP-IMRT. Three representative patients were selected for replanning with (i) whole ventricular irradiation (WVI) with opposed lateral beams plus IMRT to the primary tumor and (ii) sequential IMRT. These plans were compared to the patients' original DP-IMRT plans for dosimetric analyses.Four patients with germinoma received radiation therapy alone: 45 Gy in 1.8 Gy fractions to the primary tumor and 25 Gy in 1.0 Gy fractions to whole ventricles using a dose-painting plan. One patient with germinoma received a reduced dose of 30.6 Gy to the primary tumor after neoadjuvant chemotherapy. Patients with NGGCT (n = 6) underwent multimodality treatment including chemotherapy (n = 6) and surgery (n = 3). These patients received 54 Gy to the primary tumor and 32.4-36 Gy to the whole ventricles. Dosimetric analyses showed DP-IMRT delivered decreased mean dose to whole brain, temporal lobes, hippocampi, cochleae, and optic nerves. With median follow-up of 4 years, 3-year failure-free survival was 100% for patients with germinoma and 67% for patients with NGGCT. One patient with a pineal NGGCT experienced a local recurrence within the high dose-volume while another experienced an isolated biochemical failure.DP-IMRT is dosimetrically superior to standard IMRT techniques for sparing of normal tissues. Disease control in this small series appears at least comparable to published results.

Published
2015

48. Phantosmia During Radiation Therapy: A Report of 2 Cases.

Author

Yang, Joanna C., Khakoo, Yasmin, Lightner, Donita D., and Wolden, Suzanne L.

Subjects
*SMELL disorders, *RADIOTHERAPY complications, *GLIOMAS, *ASTROCYTOMAS, *FRONTAL lobe
Abstract

Phantosmia is an infrequently reported and poorly understood qualitative olfactory disorder characterized by the perception of a frequently unpleasant odor in the absence of an odorant stimulus. Peripheral phantosmia is hypothesized to involve abnormally active olfactory receptor neurons while central phantosmia is theorized to be the result of hyperactive neurons in the cortex. The authors present a case report that describes 2 patients with incomparable tumors and radiation fields who both experienced phantosmia featuring a halitosis-like odor during their courses of radiation therapy. Both the 6-year-old with diffuse intrinsic pontine glioma and the 15-year-old with World Health Organization grade II-III astrocytoma in the bifrontal lobes experienced significant distress and decreased quality of life during treatment because of the phantosmia, which resolved after completion of radiation therapy. To the best of the authors’ knowledge, these are the first descriptions of phantosmia during focal or whole-brain radiation therapy. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

49. PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma.

Author

Lo AC, James LP, Prica A, Raymakers A, Peacock S, Qu M, Louie AV, Savage KJ, Sehn LH, Hodgson D, Yang JC, Eich HTT, Wirth A, and Hunink MGM

Subjects
Canada, Cost-Benefit Analysis, Humans, Quality-Adjusted Life Years, Lymphoma, Follicular diagnostic imaging, Lymphoma, Follicular radiotherapy, Positron Emission Tomography Computed Tomography
Abstract

The objective was to assess the cost-effectiveness of staging PET/CT in early-stage follicular lymphoma (FL) from the Canadian health-care system perspective. Methods: The study population was FL patients staged as early-stage using conventional CT imaging and planned for curative-intent radiation therapy (RT). A decision analytic model simulated the management after adding staging PET/CT versus using staging CT alone. In the no-PET/CT strategy, all patients proceeded to curative-intent RT as planned. In the PET/CT strategy, PET/CT information could result in an increased RT volume, switching to a noncurative approach, or no change in RT treatment as planned. The subsequent disease course was described using a state-transition cohort model over a 30-y time horizon. Diagnostic characteristics, probabilities, utilities, and costs were derived from the literature. Baseline analysis was performed using quality-adjusted life years (QALYs), costs (2019 Canadian dollars), and the incremental cost-effectiveness ratio. Deterministic sensitivity analyses were conducted, evaluating net monetary benefit at a willingness-to-pay threshold of $100,000/QALY. Probabilistic sensitivity analysis using 10,000 simulations was performed. Costs and QALYs were discounted at a rate of 1.5%. Results: In the reference case scenario, staging PET/CT was the dominant strategy, resulting in an average lifetime cost saving of $3,165 and a gain of 0.32 QALYs. In deterministic sensitivity analyses, the PET/CT strategy remained the preferred strategy for all scenarios supported by available data. In probabilistic sensitivity analysis, the PET/CT strategy was strongly dominant in 77% of simulations (i.e., reduced cost and increased QALYs) and was cost-effective in 89% of simulations (i.e., either saved costs or had an incremental cost-effectiveness ratio below $100,000/QALY). Conclusion: Our analysis showed that the use of PET/CT to stage early-stage FL patients reduces cost and improves QALYs. Patients with early-stage FL should undergo PET/CT before curative-intent RT., (© 2022 by the Society of Nuclear Medicine and Molecular Imaging.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results